Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 144807 in newly diagnosed wAMD
NCT02121522Phase 2
Key facts
- Status
- Completed
- Start
- Jun 2014
- Primary completion
- Mar 2015
- Countries
- 3
- Sponsor
- Boehringer Ingelheim
- Modality
- Small Molecules
- Drugs
- BI 144807
- Conditions
- exudative macular degeneration
01
Overview
Phase 2, open-label, single-arm trial of BI 144807 in exudative macular degeneration, sponsored by Boehringer Ingelheim. Primary endpoint: Change From Baseline in Central Retinal Thickness (CRT) as Measured by SD-OCT at Day 29. Started Jun 2014; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
BI 144807
BI 144807 administered twice daily
03
Endpoints
Primary
Change From Baseline in Central Retinal Thickness (CRT) as Measured by SD-OCT
Secondary
Change From Baseline in Neovascular Leakage Area as Assessed by FA
Incidence of Adverse Events
Change in Vital Signs
Change in ECG Parameters
Change in Clinical Laboratory Parameters
Beyond the preview
Go deeper on NCT02121522.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02121522.